BTK and B-cell chronic lymphocytic leukemia: Relapsed/refractory CLL to prior cBTKi, baseline BTK mutations, unmutated IGHV, bulky lymph nodes, XPO1 mutation and complex karyotype were more prevalent attributes in the pirtobrutinib progressive-disease subgroup.